QT
TCRR

Quantbot Technologies’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Quantbot Technologies’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-800
Closed -$2K – 2276
2022
Q1 		$2K Sell
800
-8,000
-91% -$25.2K ﹤0.01% 1574
2021
Q4 		$41K Buy
8,800
+5,500
+167% +$34.4K ﹤0.01% 1082
2021
Q3 		$28K Buy
+3,300
New +$46.6K ﹤0.01% 1217

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Quantbot Technologies's TCRR Position: Q2 2022 in Review

Quantbot Technologies sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 800 shares — an estimated $2K sold.

Quantbot Technologies first reported a position in TCRR in Q3 2021 and held it in 3 quarters. The position peaked at $41K in Q4 2021. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • Quantbot Technologies reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Quantbot Technologies sold 800 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $2K.
  • Quantbot Technologies first reported a position in TCR2 Therapeutics Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Quantbot Technologies's TCR2 Therapeutics Inc. Common Stock position peaked at $41K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on Quantbot Technologies's 13F filing for Q2 2022, filed 9 Aug 2022.